Percheron Therapeutics Management
Management criteria checks 1/4
Percheron Therapeutics' CEO is James Garner, appointed in Aug 2023, has a tenure of 1.42 years. total yearly compensation is A$824.68K, comprised of 52.7% salary and 47.3% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth A$21.00K. The average tenure of the management team and the board of directors is 1.4 years and 3.3 years respectively.
Key information
James Garner
Chief executive officer
AU$824.7k
Total compensation
| CEO salary percentage | 52.7% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.4yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully
Jun 03
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully
Nov 13We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate
Jun 08We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth
Feb 14We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely
Aug 26Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation
May 12We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully
Dec 23Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation
Jun 24We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth
Mar 11Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?
Nov 26
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$825k | AU$434k | -AU$12m |
| Mar 31 2024 | n/a | n/a | -AU$11m |
| Dec 31 2023 | n/a | n/a | -AU$11m |
| Sep 30 2023 | n/a | n/a | -AU$11m |
| Jun 30 2023 | AU$34k | n/a | -AU$11m |
Compensation vs Market: James's total compensation ($USD512.67K) is above average for companies of similar size in the Australian market ($USD283.29K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
CEO
James Garner (51 yo)
1.4yrs
Tenure
AU$824,684
Compensation
Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, serves as Non-Executive Director at Percheron Therapeutics Limited (formerly known as Antisense Therapeutics Limited) since May 08, 2023 and has been its...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 1.4yrs | AU$824.68k | 0.28% A$ 21.0k | |
| Company Secretary & CFO | less than a year | AU$324.32k | no data | |
| Chief Operating Officer | 2yrs | AU$596.05k | no data | |
| Chief Medical Advisor | no data | no data | no data |
1.4yrs
Average Tenure
Experienced Management: PER's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 1.7yrs | AU$824.68k | 0.28% A$ 21.0k | |
| Independent Non-Executive Director | 3.3yrs | AU$113.77k | 0.094% A$ 7.0k | |
| Independent Non-Executive Chair | 3.8yrs | AU$220.29k | 0.069% A$ 5.1k |
3.3yrs
Average Tenure
Experienced Board: PER's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 09:04 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Percheron Therapeutics Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Iain Wilkie | Morgans Financial Limited |
| Dr Storey | Wilsons Advisory and Stockbroking Ltd. |